Clinical Trial Update: A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT) [Phase 2]

View source ↗

Summary

Phase 2 follow-on trial TRAILBLAZER-EXT evaluating donanemab (LY3002813) with video assessments in Alzheimer's disease has completed and posted its results on 2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease
• Dementia

Drugs mentioned

• Donanemab (donanemab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease, Dementia | Phase 2 | Status: COMPLETED | Results posted: 2025-06-13